REPORT HIGHLIGHT
Carrier Screening Market size was valued at USD 2,106.8 Million in 2022, expanding at a CAGR of 14.8% from 2023 to 2030.
Carrier screening is a genetic testing method used to find abnormal genes that might lead to autosomal recessive diseases in fetuses. Pregnant people and couples can examine the likelihood that their unborn child will inherit genetic diseases from one or both of their parents using this predictive and presymptomatic testing method. For diseases including cystic fibrosis, sickle cell anemia, and Tay-Sachs disease, it entails analyzing a sample of saliva, blood, or cheek tissue to look for the presence of an abnormal gene.
Carrier Screening Market- Market Dynamics:
- Increasing emphasis on early disease detection to propel market growth.
- The expanding emphasis on early disease identification and prevention as well as the rising use of screening tests for genetic diseases are key drivers of the carrier screening market expansion, both of which are anticipated to occur throughout the forecast period. For instance, according to data from the Centers for Disease Control and Prevention (CDC) updated in May 2022, sickle cell disease affects millions of people worldwide and is especially prevalent among people whose ancestors originated from sub-Saharan Africa, Spanish-speaking areas like South America, the Caribbean, and Central America, as well as Saudi Arabia, India, and Mediterranean nations.
Carrier Screening Market- Key Insights:
- As per the analysis shared by our research analyst, the global Carrier Screening market is estimated to grow annually at a CAGR of around 14.8% over the forecast period (2023-2030)
- The Carrier Screening industry is projected to grow at a significant rate owing to the rise in funding by the government and private sector
- Based on type segmentation, the Expanded Carrier Screening segment is expected to grow at the fastest rate over the forecast period
- Based on region, North America is expected to dominate the market over the forecast period
Carrier Screening Market- Segmentation Analysis:
- The Global Carrier Screening Market is segmented based on type, medical condition, technology, end user, and Region.
- Based on type, the market is bifurcated into Expanded Carrier Screening and Targeted Disease Carrier Screening. The Expanded Carrier Screening segment is expected to grow at the fastest rate over the forecast period. The ECS, which screens for a wide range of genetic illnesses independent of ethnic origin, is the rising carrier screening type. To increase their market share, businesses are engaging in strategic activities like product creation. For instance, Mitera stated in January 2022 that it will introduce two genetic test products in the United States, one of which was an at-home extended carrier screening test that helps people assess their risk of any of 421 genetic illnesses. For customers, this improves product accessibility and convenience. Thereby, driving the segment growth over the forecast period.
Carrier Screening Market- Geographical Insights:
Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. North America is expected to dominate the market over the forecast period. It is predicted that market expansion in North America would be fueled by rising product approvals by the US Food and Drug Administration (FDA) and subsequent launches, as well as the high concentration of major firms engaged in research activities for the invention of innovative genetic testing products. For instance, Mitera declared in January 2022 that its Peaches & Me and 23Pears at-home reproductive genetic testing kits will be available in all 50 states. The first non-invasive prenatal test (NIPT) that clients may obtain online and have performed at home is Peaches & Me. It can identify the baby's gender and screen for conditions like Down syndrome as early as week 10 of pregnancy. Thus, this is expected to dominate the market over the forecast period.
Carrier Screening Market- Competitive Landscape:
Leading companies in the worldwide Carrier Screening market are stepping up their R&D efforts to diversify their product offerings. Additionally, these market participants use strategic alliances and partnerships that promote growth. The key players operating in the market include Myriad Genetics, Inc, Cepheid, Illumina, Thermo Fisher Scientific Inc., F.Hoffmann-La Roche Ltd, Laboratory Corporation of America Holdings, Otogenetics, MedGenome, GeneTech and Centogene N.V.
Recent Developments:
In December 2022, a strategic relationship was established between Oxford Nanopore Technologies and Bio-Techne to provide an integrated wet- and dry-lab kit for genotyping 11 genes necessary for carrier screening.
Key features of the study:
- This proposed research study on Carrier Screening market provides market size (US$ million), compound annual growth rate (CAGR %) and forecast estimation (2023-2030), considering 2022 as the base year
- The report provides the client the latest up-to-date and trending insights about the Carrier Screening market.
- The research report elucidates potential growth opportunities across different segments/countries and explains attractive investment proposition matrix for Carrier Screening market
- The overall report identifies new investment opportunities, challenges faced by established players, and growth factors to sustain in the Carrier Screening market
- Impact of COVID-19 on Carrier Screening market size, forecast, CAGR, and market dynamics are discussed in detail under the research scope. Detailed insight on Carrier Screening market post-COVID will also be covered.
- In order to give the users of this report a comprehensive view on the Carrier Screening market, we have also included competitive landscape and key innovator analysis for the Carrier Screening market.
- The study encompasses a growth prospect mapping analysis, wherein all the industry segments are benchmarked based on their market size, growth rate and attractiveness.
- The report offers detailed company profiling featuring major market participants which will help users to understand their financial information and strategic initiatives of players operating in the Carrier Screening market.
- In addition, the report also unveil the important acquisitions & mergers, collaborations & joint ventures, new launch, research & development, regional expansion of major participants involved in the market on global as well as regional level.
- The global Carrier Screening market report primarily caters to various stakeholders in this industry including suppliers, investors, new entrants, distributors, and financial analysts
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL CARRIER SCREENING MARKET KEY PLAYERS
- Thermo Fisher Scientific Inc
- Cepheid
- Illumina
- Myriad Genetics, Inc
- F.Hoffmann-La Roche Ltd
- Laboratory Corporation of America Holdings
- Otogenetics
- MedGenome
- GeneTech
- Centogene N.V.
GLOBAL CARRIER SCREENING MARKET, BY TYPE
- Expanded Carrier Screening
- Targeted Disease Carrier Screening
GLOBAL CARRIER SCREENING MARKET, BY MEDICAL CONDITION
- Cystic Fibrosis
- Tay-Sachs
- Gaucher Disease
- Sickle Cell Disease
- Spinal Muscular Atrophy
- Others
GLOBAL CARRIER SCREENING MARKET, BY TECHNOLOGY
- DNA Sequencing
- Polymerase Chain Reaction
- Microarrays
- Others
GLOBAL CARRIER SCREENING MARKET, BY END USER
- Hospitals
- Laboratories
- Physician Offices & Clinics
- Others
GLOBAL CARRIER SCREENING MARKET, BY REGION
- North America
- The U.S.
- Canada
- Europe
- Germany
- France
- Italy
- Spain
- United Kingdom
- Russia
- Netherlands
- Sweden
- Poland
- Rest of Europe
- Asia Pacific
- India
- China
- South Korea
- Japan
- Australia
- Thailand
- Indonesia
- Philippines
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
- The Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA